---
title: 'Dual-Labeled Small Peptides in Cancer Imaging and Fluorescence-Guided Surgery:
  Progress and Future Perspectives'
date: '2025-02-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/40005958/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250226171103&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Dual-labeled compounds that combine radiolabeling and fluorescence labeling
  represent a significant advancement in precision oncology. Their clinical implementation
  enhances patient care and outcomes by leveraging the high sensitivity of radioimaging
  for tumor detection and taking advantage of fluorescence-based optical visualization
  for surgical guidance. Non-invasive radioimaging facilitates immediate identification
  of both primary tumors and metastases, while fluorescence imaging assists ...
disable_comments: true
---
Dual-labeled compounds that combine radiolabeling and fluorescence labeling represent a significant advancement in precision oncology. Their clinical implementation enhances patient care and outcomes by leveraging the high sensitivity of radioimaging for tumor detection and taking advantage of fluorescence-based optical visualization for surgical guidance. Non-invasive radioimaging facilitates immediate identification of both primary tumors and metastases, while fluorescence imaging assists ...